Nexus Pharmaceuticals Receives FDA Approval for Potassium Chloride in Water for Injection
LINCOLNSHIRE, Ill.–(BUSINESS WIRE)–#aprated–Nexus Pharmaceuticals announced today that it has received U.S. Food and Drug Administration (FDA) approval for Potassium Chloride in Water for Injection in 10mEq/100mL, 10mEq/50mL, 20mEq/100mL, 40mEq/100mL and 20mEq/50mL Single-Dose IV bags.
“This approval showcases Nexus’ commitment to developing and commercializing critically needed and historically scarce IV solutions,” said Mariam S. Darsot, President and Chief Executive Officer of Nexus Pharmaceuticals. “IV solutions have been under pressure and in short supply periodically over the last five years due to logistical constraints and supplier concentration. Nexus hopes to alleviate some of those issues by bringing this product to market and giving customers alternatives when the product is needed most.”
Nexus Pharmaceuticals’ Potassium Chloride in Water for Injection will be available in cartons of 24 IV bags and the product is an AP-rated generic.
About Potassium Chloride in Water for Injection
Potassium Chloride Injection is indicated in the treatment of potassium deficiency states when oral replacement is not feasible. It is intended for the maintenance of Serum K+ levels and for potassium supplementation in fluid restricted patients who cannot accommodate additional volumes of fluid associated with potassium solutions of lower concentration.
For prescribing information, please see the following link.
About Nexus Pharmaceuticals Inc.
Nexus Pharmaceuticals Inc., a US-based healthcare company, specializes in innovative processes to make difficult-to-manufacture specialty and generic drugs that are easier to use, less labor intensive, and more streamlined in practice. Nexus ensures that its high-quality FDA-approved drugs fulfill a critical unmet medical need and delivers dependable life-saving treatment options when and where they’re needed most. For more information about Nexus Pharmaceuticals, including our new state-of-the-art Wisconsin manufacturing facility and Live Cam, please visit https://www.nexuspharma.net/project-tomorrow/.
Contacts
Deana Mndrucic
[email protected]
847-996-3790
